In February 2026, Robert F. Kennedy Jr. — now heading the Department of Health and Human Services — announced that 14 peptides previously removed from legal compounding would be restored to Category 1 status. For physicians and patients who have been watching this space, this is significant. But the details matter more than the headlines.
What happened in 2023: the Category 2 ban
In late 2023, the FDA reclassified 19 peptides from Category 1 (eligible for compounding) to Category 2 (ineligible). The practical effect was immediate: licensed compounding pharmacies could no longer legally produce these molecules. BPC-157, TB-500, CJC-1295, Ipamorelin, and over a dozen others went dark overnight.
The stated rationale was safety — specifically, insufficient evidence that these peptides met the standards for compounded drugs. But the real-world consequence was a gray market problem. Patients who had been receiving these peptides through legitimate, physician-supervised channels were suddenly cut off. Many turned to unregulated sources — research chemical sites, overseas suppliers, and underground compounders with no quality controls. The ban did not eliminate demand. It eliminated oversight.
What RFK announced in February 2026
Kennedy's HHS directive signals that 14 of the 19 banned peptides are expected to return to Category 1 classification. This means licensed, FDA-registered compounding pharmacies will again be able to legally produce these molecules — provided they are prescribed by a licensed physician for an individual patient.
It is important to be precise about what this is and what it is not. This is not FDA approval. None of these peptides will carry an FDA-approved indication. This is compounding eligibility — a legal framework that allows pharmacies to produce them under specific regulatory conditions.
Which peptides are expected to return
- BPC-157 — tissue repair and gut healing peptide, one of the most widely used in regenerative medicine
- TB-500 (Thymosin Beta-4) — promotes wound healing, reduces inflammation, supports tissue regeneration
- CJC-1295 — growth hormone-releasing hormone analog, stimulates natural GH production
- Ipamorelin — selective growth hormone secretagogue, often paired with CJC-1295
- GHK-Cu — copper peptide involved in wound healing, collagen synthesis, and skin repair
- Sermorelin — GHRH analog that restores natural growth hormone pulsatility
- Tesamorelin — GHRH analog with FDA approval for HIV-associated lipodystrophy, broader compounding use expected
- DSIP (Delta Sleep-Inducing Peptide) — neuropeptide associated with sleep regulation
Additional peptides on the expected restoration list include AOD-9604, Epithalon, KPV, Selank, and Semax. The full list is subject to final regulatory confirmation.
What Category 1 actually means
Category 1 status means a peptide can be legally compounded by a licensed 503A or 503B pharmacy. It requires a valid physician prescription written for an individual patient. The peptide is not available over the counter. It is not FDA-approved for any indication. It still requires legitimate physician oversight, clinical documentation, and proper patient evaluation.
This is the framework that existed before the 2023 reclassification, and it worked. Physicians prescribed. Pharmacies compounded. Patients received quality-controlled molecules under medical supervision. The system was not perfect, but it was functional — and meaningfully safer than the gray market that replaced it.
Ready for BPC-157 the day it's legal?
Join the Waitlist →What hasn't changed yet
As of April 2026, the FDA has not published a formal reclassification order. The HHS announcement set direction, but the regulatory machinery has not completed its cycle. This means that, technically, these peptides remain Category 2 and cannot be legally compounded today. Premium compounding pharmacies are building waitlists and preparing supply chains, but none are shipping yet.
The smart play for patients: establish a relationship with a physician-led protocol now. Get your intake on file. Be first in line when the reclassification clears — not scrambling to find a provider after everyone else has already placed their orders. The pharmacies that maintained quality standards through the ban will have limited initial capacity.
The peptide landscape is shifting back toward physician oversight and pharmaceutical-grade production. That is a good thing. If you have been waiting for BPC-157, TB-500, or any of these molecules to return to legal channels, the signal is clear: it is coming. Be ready.